Fritextsökning
Artiklar per år
Innehållstyper
-
Surgical Science bjuder halv miljard för brittiskt bolag
Svenska Surgical Science lägger ett rekommenderat bud på brittiska Intelligent Ultrasound på cirka 45,2 miljoner pund, motsvarande omkring 630 miljoner kronor.
-
Hypothesis testing versus conspiracy theory
"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Johan Liwing blir vd på Lipigon
Lipigon Therapeutics har utsett Johan Liwing till ny vd.
-
Lilly recruits top Swedish researcher in Alzheimer´s
One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while no such association was found in men, according to a new large Swedish study.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindgren paints a partly different picture in a new book about the French master's life, health and attitude towards physicians.
-
Seminarier får svensk life science att blomstra: “Fyller rummet med rätt personer”
Minimala risker, maximal räckvidd. Genom ett unikt koncept hjälper nu Medicon Valley Alliance företag att skapa mötesplatser där rätt personer samlas – och intresset ökar.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks approved treatment alternatives. "We can't do that on our own – our entire R&D activities are about working together with others," says the company's CEO Jens Lindberg.
-
IGN slår ner mot film från Leo Pharma
En film från Leo Pharma, där en läkare beskriver ett läkemedel som ”really over the top” och att det leder till ”really incredible results”, fälls av IGN.
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical companies are highlighted as a success factor. “Everyone has heard of Novo Nordisk
-
Nio förslag från branschen för bättre life science i EU
Ett enhetligt regelverk för kliniska prövningar, en både holistisk och målinriktad life science-strategi – och ett särskilt kontor inom EU-kommissionen för att koordinera life science-frågor. Så lyder några av förslagen från nordiska branschorganisationer till EU.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
33 kvinnor i Uppsala fick livmodern bortopererad i onödan
Efter felaktiga diagnoser vid Akademiska sjukhuset i Uppsala har det opererats bort 33 livmödrar i onödan. ”En fruktansvärd nyhet”, kommenterar sjukvårdsminister Acko Ankarberg Johansson (KD).
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the decision to create a joint profile for the two cities is strongly supported. He mentions that around 50 stakeholders were asked last winter if they were in favour of a joint cluster and that “the answer was a resounding yes”.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
Olivia Wigzell blir kvar som generaldirektör för Folkhälsomyndigheten
Regeringen utser Olivia Wigzell till generaldirektör för Folkhälsomyndigheten, FHM, på permanent basis. Hon har de senaste månaderna vikarierat på posten.
-
Viruslarm avblåst i Tyskland – men utbrottet fortsätter i Rwanda
Farhågorna om misstänkt blödarsjuka från marburgvirus i Hamburg visade sig vara falskt alarm. Samtidigt fortsätter utbrottet av den dödliga infektionen i centralafrikanska Rwanda.
-
Roche i storaffär om portfölj inom bröstcancerområdet
Schweiziska Roche Pharmaceuticals dotterbolag förvärvar portfölj inom bröstcancerområdet från amerikanska biotechföretaget Regor Pharmaceuticals.
-
Senzime tar in kapital för fortsatt kommersiell expansion
Medtechbolaget Senzime har beslutat att genomföra en riktad nyemisson. Bolaget planerar att ta in cirka 86 miljoner kronor.
-
Moderna fälls efter 20 000-kronorserbjudande till barn
Moderna kritiseras i Storbritannien för ett felaktigt meddelande där barn erbjöds 1 500 pund, motsvarande över 20 000 kronor, för deltagande i en klinisk studie av bolagets covid-vaccin.
BREAKING